Dose escalation trial of cyclophosphamide with sargramostim in the treatment of central nervous system (CNS) neoplasms
| Autor: | Michael L. Graham, Darell D. Bigner, Beverly Hockenberger, Abbe Sue Rubin, Mark Brown, Herb Fuchs, Joanne Kurtzberg, Gary J. Felsberg, Ruth Fredericks, O. Michael Colvin, Albert Moghrabi, Margaret Duncan-Brown, Dagmar Oette, Henry S. Friedman, Daniel H. Lachance, S. Clifford Schold, Frances Ann Hayes, Barry Golembe, Elizabeth S. Stewart, Iley Browning, Robert D. Tien, Lee Ferrell, Tracy Kerby |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Neutropenia Adolescent Cyclophosphamide medicine.medical_treatment Urology Sargramostim medicine Humans Child Medulloblastoma Chemotherapy Dose-Response Relationship Drug Germinoma Brain Neoplasms business.industry Granulocyte-Macrophage Colony-Stimulating Factor Infant Middle Aged medicine.disease Recombinant Proteins Surgery Radiation therapy Granulocyte macrophage colony-stimulating factor Oncology Child Preschool Pediatrics Perinatology and Child Health Absolute neutrophil count Female business medicine.drug |
| Zdroj: | Medical and Pediatric Oncology. 24:241-247 |
| ISSN: | 1096-911X 0098-1532 |
| Popis: | We conducted a dose escalation trial of cyclophosphamide plus Sargramostim in the therapy of patients with newly diagnosed or recurrent central nervous system tumors. Cyclophosphamide was administered at doses ranging between 1.0 and 2.5 g/m2 daily for two doses. Sargramostim was administered at a fixed dose of 250 μg/m2 subcutaneously twice a day beginning 24 hours after the second cyclophosphamide dose and continuing through the leukocyte nadir until the absolute neutrophil count (ANC) was >1,000 cells/μl for two consecutive days. The MTD for patients who had not received any prior chemotherapy and who had received either no radiotherapy or radiotherapy confined to the cranium was 2.0 g/m2 daily for two doses. The MTD for patients previously treated with chemotherapy or neuraxis radiotherapy was also 2.0 g/m2 daily for two doses. Responses were seen in patients with medulloblastoma (8/9), glioblastoma multiforme (2/13), germinoma (1/1), and pineoblastoma (1/2). © 1995 Wi1ey-Liss Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text